CONDITIONAL MUTANTS OF INFLUENZA VIRUS M2 PROTEIN

Abstract: A mutant of Influenza virus M2 protein is described, which is capable of causing growth arrest in mammalian cells. Its use in a conditional cell deletion system is provided.

Description: COND ITIONAL MUTANTS OF INFLUENZA VIRUS M2 PROTEIN The present invention concerns a process for creating conditional lethal mutations in selected cells. In particular, the invention concerns means for arresting specific tissue development or destroying specific tissues in organisms in vivo. M2, the spliced segment of the Influenza A virus matrix (M) gene, is a 97 amino acid integral membrane polypeptide containing a single membrane-spanning region. In the virus and infected cell membranes, M2 polypeptides associate into tetramers to form proton channels, thereby providing a function essential for virus replication (Holsinger, L. J. and Lamb, R. A. (1991), Virology 183: 32-43; Sugrue R. L. and Hay, A. J. (1991), Virology 180: 617-624; Pinto, L.. et al. (1992), Cell 69: 517-528) by permitting proton transport in the host endosome duπng infection and in the trans-Golgi network during viral protein processing. The available therapeutic agents for Influenza A virus, amantadme and πmantadine, function by blocking M2 proton channel activity (Hay, A. (1992), Seminars in Virology 3: 21-30). Expression of M2 in certain systems, such as baculovirus or Xenopus oocytes (Schroeder et al, (1994) J Gen Virol 75:3477-3484) leads to a slow down of growth, or cell death, manifested as reduced expression of M2 protein. These adverse effects may be reversed by administration of amantadine or its analogue rimantadine. However, adverse effects have not been demonstrated in mammalian cells, which continue to grow in the presence of M2 protein. At present, the only available conditional lethality system which may be transfected into cells is the loxP-Cre system. This combination of Cre recombinase and loxP sites, which are targeted by the recombinase, allows specific gene ablation (see Gu et al, (1994) Science 265:103). Summary of the Invention In a first aspect of the present invention, there is provided a mutant of Influenza virus M2 protein capable of arresting the growth of a mammalian cell. It has surprisingly been shown that cells transfected with mutants of influenza virus M2 protein are incapable of growth The growth arrest observed appears not to be due to toxicity of the M2 mutants, but to arrest of the cell cycle m transfected cells, preventing further cell development and growth The arrest is believed to be due to the conversion of the M2 protein from a proton channel to an ion channel, which has disadvantageous effects in mammalian cells and leads to the arrest of the cell cycle in GO or Gl. The arrest may be rescued by adding an M2-bloc mg agent, such as amantadme or πmantadine. These molecules, and their analogues, are capable of impeding wild-type and mutant M2 function by physically blocking the transmembrane pore which permits ion transport. In a second aspect, the invention relates to a transgemc non-human mammal encoding, within at least a subpopulation of the cells thereof, a transgene expressing an influenza virus M2 mutant according to the first aspect of the invention. Preferably, the M2 mutant transgene is under tissue specific control and is thus only expressed in a certain tissue or tissues Administration of an M2-blockmg agent to the animal will prevent the growth-arresting effects of the M2 mutant protein Aπest of tissue growth can thus be tπggered by withdrawing the M2-blockmg agent. This event can be timed as desired, m order to induce tissue and temporal specific arrest of cell growth. This provides an valuable tool for the study of the development of tissues. In a third aspect, the invention relates to a method for arresting the growth of a cell compπsing inserting into the cell a transgene encoding an influenza virus M2 mutant according to the first aspect of the invention. In a fourth aspect, the invention relates to a genetic construct compπsing a nucleic acid encoding an influenza M2 mutant according to the first aspect of the invention. Detailed Description of the Invention The present invention relates to a mutant of influenza virus M2 protein, which is defined by its ability to aπest growth of mammalian cells. As used herein, "mutant" defines any departure from the structure of wild-type M2 protein. Thus, it includes vaπants in ammo acid sequence as well as other deπvatives, as set forth in more detail below. "M2" refers to the M2 protein of influenza A virus In general, this term refers to M2 protein deπved from any isolate of influenza A virus. Preferably, the isolate is an avian influenza virus Mutants of influenza virus M2 may contain ammo acid deletions, additions or substitutions, subject to the requirement to maintain the ion channel activity of influenza virus M2 descπbed herein. This includes mutations which are not m themselves responsible for the effects observed m the invention. Thus, conservative ammo acid substitutions may be made substantially without alteπng the nature of influenza virus M2, as may truncations from the 5' or 3' ends. Deletions and substitutions may moreover be made to the fragments of influenza virus M2 compπsed by the invention. M2 mutants may be produced from nucleic acid which has been subjected to in vitro mutagenesis resulting e.g. m an addition, exchange and/or deletion of one or more ammo acids The fragments, mutants and other deπvatives of M2 preferably retain substantial homology with the M2 sequence set forth m SEQ. ID. No. 1, taken from the Weybπdge isolate of avian influenza A virus. As used herein, "homology" means that the two entities share sufficient characteπstics for the skilled person to determine that they are similar in oπgm and function. Preferably, homology is used to refer to sequence identity. Thus, the deπvatives of M2 preferably retain substantial sequence identity with SEQ. ID. No. 1 (or its encoded polypeptide product shown in SEQ. ID. No. 2). Preferably, the sequences retain substantial homology with the coding region of SEQ. ID. No. 1, which stretches from positions 26 to 319 thereof. Advantageously, they retain substantial homology with a 25 nucleotide o gonucleotide deπved from SEQ. ID. No. 1. In an alternative embodiment, the sequences may be homologous to SEQ. ED. No. 3, which is taken from the Rostock isolate of avian influenza A virus The M2 coding sequence in SEQ. LD. No. 3 is located between positions 1 to 26 and 715 to 982. In a further embodiment, the M2 sequence of the invention may be homologous to a sequence selected from the group consisting of all possible sequences encoding the polypeptide of SEQ. ID. No. 2, and all possible sequences encoding the polypeptide encoded m the above-identified coding regions of SEQ. ED. No. 3 "Substantial homology", where homology indicates sequence identity, means more than 40% sequence identity, preferably more than 45% sequence identity and most preferably a sequence identity of 50% or more, as judged by direct sequence alignment and compaπson. Sequence homology (or identity) may moreover be determined using any suitable homology algoπthm, using for example default parameters Advantageously, the BLAST algoπthm is employed, with parameters set to default values The BLAST algoπthm is descπbed in detail at http://www.ncbi.mh.gov BLAST blast_help.html, which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters. Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10. BLAST (Basic Local Alignment Search Tool) is the heuπstic search algoπthm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlm and Altschul (see http://www.ncbi.nih.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs were tailored for sequence similaπty searching, for example to identify homologues to a query sequence The programs are not generally useful for motif-style searching. For a discussion of basic issues in similaπty searching of sequence databases, see Altschul et al. (1994) Nature Genetics 6:119-129 The five BLAST programs available at http //www ncbi.nlm nih.gov perform the following tasks blastp compares an ammo acid query sequence against a protein sequence database, blastn compares a nucleotide query sequence against a nucleotide sequence database, blastx compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database, tblastn compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands) tblastx compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database BLAST uses the following search parameters- HISTOGRAM Display a histogram of scores for each search, default is yes. (See parameter H in the BLAST Manual) DESCRIPTIONS Restπcts the number of short descπptions of matching sequences reported to the number specified; default limit is 100 descπptions. (See parameter V in the manual page). See also EXPECT and CUTOFF. ALIGNMENTS Restπcts database sequences to the number specified for which high- scoπng segment pairs (HSPs) are reported; the default limit is 50 If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascπbed the greatest statistical significance are reported. (See parameter B in the BLAST Manual) EXPECT The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Kar n and Altschul (1990). If the statistical significance ascπbed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stπngent, leading to fewer chance matches being repoπed Fractional values are acceptable (See parameter E m the BLAST Manual) CUTOFF Cutoff score tor reporting high-sconng segment pairs The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascπbed to them is at least as high as would be ascπbed to a lone HSP having a score equal to the CUTOFF value Higher CUTOFF values are more stπngent, leading to fewer chance matches being reported. (See parameter S m the BLAST Manual) Typically, significance thresholds can be more intuitively managed using EXPECT MATRIX Specify an alternate scoπng matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matnx is BLOSUM62 (Henikoff & Hemkoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matπces are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response. STRAND Restπct a TBLASTN search to just the top or bottom strand of the database sequences; or restπct a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence. FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17.149-163. or segments consisting of short-Peπodicity internal repeats, as determined by the XNU program of Claveπe & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see http.//www ncbi.nlm.nih.gov) Filteπng can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or prolme-πch regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences. Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g , "NNNNNNNNNNNNN") and the letter "X" m protein sequences (e.g., "XXXXXXXXX") Filtenng is only applied to the query sequence (or its translation products), not to database sequences Default filtenng is DUST for BLASTN, SEG for other programs. It is not unusual for nothing at all to be masked by SEG. XNU, or both, when applied to sequences in SWISS-PROT, so filtenng should not be expected to always yield an effect. Furthermore, m some cases, sequences are masked m their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect. NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name. Most preferably, sequence compaπsons are conducted using the simple BLAST search algoπthm provided at http://www.ncbi.nlm.nih.gov/BLAST. The mutant provided by the present invention also includes deπvatives which are amino acid mutants, glycosylation vaπants and other covalent deπvatives of influenza virus M2 which retain the growth-arresting or cytotoxic physiological properties of M2 as set forth herein. Exemplary deπvatives include molecules wherein influenza virus M2 is covalently modified by substitution, chemical, enzymatic, or other appropπate means with a moiety other than a naturally occumng amino acid Preferably, the invention relates to mutants deπved from M2 protein isolated from avian influenza A virus (Weybπdge or Rostock) Advantageously, M2 is isolated from Weybπdge influenza A virus However, the invention also relates to all vaπants of M2 capable of acting as proton or ion channels Thus, also included are naturally occurring vaπants of influenza virus M2 found other influenza isolates Such vaπants may be encoded by a related gene of the same gene familv , by an allehc vaπant of a particular gene, a chimera of M2 genes, or represent an alternative splicing vanant of an influenza virus M2 gene. Vaπants which retain common structural features can be fragments of influenza virus M2 Fragments of influenza virus M2 compnse smaller polypeptides denved from therefrom Preferably, smaller polypeptides deπved from influenza virus M2 according to the invention define a single feature which is characteπstic of influenza virus M2 Fragments may m theory be almost any size, as long as they retain the ion channel activity of influenza virus M2 descπbed herein The mutations responsible for endowing M2 with growth-arresting properties in mammalian cells are advantageously located in a part of the molecule which is responsible for, or associated with, the formation of a proton channel m a mammalian membrane in wild-type M2 Advantageously, the mutations are m the transmembrane domain of M2. The transmembrane domain may be defined as that part of the M2 polypeptide encoded by ammo acids 26 to 43 of the Weybπdge isolate M2, or equivalents thereof Preferably, the M2 mutants of the invention are mutated in order to endow the M2 polypeptide with ion channel activity in mammalian cells. By "ion channel activity" it is intended to denote that the activity of the M2 protein is changed from that of a proton channel, as is the case m wild-type M2, to that of a channel which allows the passage of ions other than protons Preferably, it will allow the passage of substantially any inorganic ion, advantageously any ion Advantageously, mutations are effected in a residue which is involved in the formation or maintenance of the α-hehcal structure of the transmembrane domain Preferably, the mutation is effected at or adjacent to position 37 The posιtιon(s) selected for mutation are advantageously altered by am o acid substitution. Prefeπed substitutions are those which affect ion transport in the proton channel of M2. For example, protonation of H37 in the transmembrane domain is believed to be cπtical for proton channel function Alteration of this residue, or of other residues which may affect its protonation, are expected to influence ion transport in M2. Preferably, an Ala residue is substituted at position 37 However, other residues may be substituted at this or other positions, for example Glycine, Argmine, Gluta ic acid, Glutamine or Seπne The substitution of am o acids other than Alanine at position 37 may endow the mutant with a different phenotypic characteπstic to the Alanine mutant. Thus, whilst the Alanine mutant functions as an altered ion channel which allows K + transport and is responsible for the aπest of the growth of the transfected cells in Gl or GO. other mutants may display different means of growth aπest and/or may be toxic to the transfected cell When placed under the control of a tissue-specific promoter or suitable control sequence, such mutants may moreover be capable of providing conditional lethality Mutations may be performed by any method known to those of skill in the art. Preferred, however, is site-directed mutagenesis of a nucleic acid sequence encoding the kinase of interest A number of methods for site-directed mutagenesis are known in the art, from methods employing single-stranded phage such as M13 to PCR-based techniques (see "PCR Protocols' A guide to methods and applications", M.A. Innis, D.H. Gelfand, J.J. Sninsky, TJ. White (eds.). Academic Press, New York, 1990). Preferably, the commercially available Altered Site El Mutagenesis System (Promega) may be employed, according to the directions given by the manufacturer Alternatively, the sited-directed mutagenesis method according to Kunkel et al, (1987) Enzymology 159:367 may be employed. The M2 mutant of the invention is capable of causing growth arrest m mammalian cells. In the term "growth aπest", all forms of growth inhibition are included. For example, the term includes toxicity, which leads to slowing of cell growth and ultimately to cell death, the inhibition of cell division and other forms of cell growth inhibition. Preferably, the term refers to the prevention of cells from proceeding through any particular phase of the cell cycle, thus preventing cell growth and division Advantageously, growth arrested cells are aπested in phase GO or Gl of the cell cycle Thus, the invention provides mammalian cells transfected with an M2 mutant according to the above aspect of the invention. Examples of useful mammalian host cell lines are epithelial or fibroblastic cell lines such as Chinese hamster ovary (CHO) cells, NTH 3T3 cells, HeLa cells or 293T cells. The host cells referred to in this disclosure compπse cells in in vitro culture as well as cells that are within a host animal DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art. Stably transfected mammalian cells may be prepared by transfectmg cells with an expression vector having a selectable marker gene, and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene to monitor transfection efficiency To produce such stably or transiently transfected cells, the cells should be transfected with a sufficient amount of M2-encodmg nucleic acid to form M2. The precise amounts of DNA encoding M2 may be empiπcally determined and optimised for a particular cell and assay. Host cells are transfected or, preferably, transformed with expression or cloning vectors as descπbed below and cultured in conventional nutnent media modified as appropπate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Heterologous DNA may be introduced into host cells by any method known in the art, such as transfection with a vector encoding a heterologous DNA by the calcium phosphate coprecipitaUon technique or by electroporation Numerous methods of transfection are known to the skilled worker m the field. Successful transfection is generally recognised when any indication of the operation of this vector occurs in the host cell. Transformation is achieved using standard techniques appropπate to the particular host cells used. Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA. and selection of transfected cells are well known in the art (see, e.g. Sambrook et al (1989) Molecular Cloning A Laboratory Manual, Second Edition, Cold Spnng Harbor Laboratory Press). Transfected or transformed cells are cultured using media and cultuπng methods known in the art, preferably under conditions, whereby M2 encoded by the DNA is expressed. The composition of suitable media is known to those in the art, so that they can be readily prepared. Suitable cultuπng media are also commercially available The invention moreover concerns a transgemc non-human mammal encoding, within at least a subpopulation of the cells thereof, a transgene expressing an influenza virus M2 mutant according to the preceding aspect of the invention. In the transgemc animal in question, the cells in which the mutant is expressed will be unable to grow. Preferably, therefore, the transgene is under the control of a tissue-specific control element. This may include one or more of a tissue-specific promoter, enhancer or locus control region (LCR). Moreover, the transgene may be integrated at a specific position in the genome of the host mammal, which may provide tissue specificity as a result of the environment in which the transgene is integrated. Transgemc animals may be generated by any suitable technique, including nuclear microinjection and the use of ES cells to produce chimeras, which are known to those skilled in the art However, nuclear microinjection is prefeπed as the likelihood of transfectmg all the cells of the desired tissue with the transgene is increased. The mutants according to the invention may be regulated by the use of an M2 blocking agent It is known that certain agents, typically amantadme, πmantadine and equivalents thereof, are capable of inhibiting the function of wild-type M2 by blocking the proton channel pore The same agents may be used together with the mutants of the invention to block ion channel activity and thus negate the effects thereof Thus, the growth-aπest phenotype may be rescued by admimsteπng πmantadine, amantadme or equivalents thereof to cells or transgemc animals expressing the mutants according to the invention When the blocking agent is removed, the M2 mutant becomes operational and induces the growth aπest phenotype m cells which express it The invention is thus useful for the study of the development of tissues in transgemc animals, and in particular those tissues not normally accessible to manipulation For example, the invention is applicable to the study of the tissues of the immune system In a further aspect, the invention concerns a genetic construct compπsing a nucleic acid encoding an influenza M2 mutant according to the preceding aspects of the invention As used herein, "genetic construct" refers to nucleic acid molecules which encode the stated constituents In particular, the term includes discrete elements, such as vectors or plasmids, that are used to introduce heterologous DNA into cells for either expression or replication thereof Selection and use of such vehicles are well within the stall of the artisan. Many vectors are available, and selection of appropπate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for DNA expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. Both expression and cloning vectors generally contain nucleic acid sequence that enable the vector to replicate in one or more selected host cells Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes oπgins of replication or autonomously replicating sequences Such sequences are well known for a vaπety of bacteπa, yeast and viruses The oπgm of replication from the plasmid pBR322 is suitable for most Gram-negative bacteπa, the 2m plasmid oπgin is suitable for yeast, and vaπous viral oπgins (e g SV 40, polyoma, adenovirus) are useful for cloning vectors m mammalian cells Generally, the oπgin of replication component is not needed for mammalian expression vectors unless these are used in mammalian cells competent for high level DNA replication, such as COS cells Most expression vectors are shuttle vectors, l e thev are capable of replication in at least one class of organisms but can be transfected into another class of organisms for expression For example, a vector is cloned m E coll and then the same vector is transfected into yeast or mammalian cells even though it is not capable of replicating independently of the host cell chromosome Thus, the vector may be suitable for integrating its DNA into the genome of the mammalian host cell Advantageouslv an expression and cloning vector may contain a selection gene also refeπed to as selectable marker This gene encodes a protein necessary for the survival or growth of transformed host cells grown m a selective culture medium Host cells not transformed with the vector containing the selection gene will not survive in the culture medium Typical selection genes encode proteins that confer resistance to antibiotics and other toxms, e g ampicillm, neomycm, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply cπtical nutπents not available from complex media As to a selective gene marker appropπate for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene Suitable markers for yeast are, for example, those conferring resistance to antibiotics G418, hygromycin or bleomycm, or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2, TRP1, or HIS3 gene Since the replication of vectors is conveniently done in E. coh, an E coli genetic marker and an E. coli oπgin of replication are advantageously included These can be obtained from E. coli plasrmds, such as pBR322. Bluescπpt© vector or a pUC plasmid, e.g. pUC18 or pUC19, which contain both E coh replication oπgin and E coli genetic marker confernng resistance to antibiotics, such as ampicillm. Genetic constructs according to the invention preferably contain a promoter that is recognised by the host organism and is operably linked to the M2 nucleic acid. Such a promoter may be inducible or constitutive Preferably, the promoter is operably linked to DNA encoding M2 by removing the promoter from the source and inserting the isolated promoter sequence into the vector The term "operably linked" refers to a juxtaposition wherein the components descnbed are in a relationship permitting them to function in their intended manner A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences Prefeπed expression vectors are bacteπal expression vectors which compnse a promoter of a bacteπophage such as phagex or T7 which is capable of functioning in the bacteπa. In one of the most widely used expression systems, the nucleic acid encoding the fusion protein may be transcπbed rrom the vector by T7 RNA polymerase (Studier et al, Methods m Enzymol 185, 60-89 1990) In the E. coh BL21(DE3) host strain, used in conjunction with pET vectors, the T7 RNA polymerase is produced from the λ-lysogen DE3 in the host bacteπum, and its expression is under the control of the IPTG inducible lac UV5 promoter. This system has been employed successfully for over-production of many proteins. Alternatively the polymerase gene may be introduced on a lambda phage by infection with an mt- phage such as the CE6 phage which is commercially available (Novagen, Madison, USA) other vectors include vectors containing the lambda PL promoter such as PLEX (Invitrogen, NL) , vectors containing the trc promoters such as pTrcHιsXpress Tm (Invitrogen) or pTrc99 (Pharmacia Biotech, SE) , or vectors containing the tac promoter such as pKK223-3 (Pharmacia Biotech) or PMAL (New England Biolabs, MA, USA). M2 gene transcription from vectors in mammalian hosts may be controlled by promoters deπved from the genomes of viruses such as polyoma virus, adenovirus, fowlpox virus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), a retrovirus and Simian Virus 40 (SV40), from heterologous mammalian promoters such as the actin promoter or a very strong promoter, e.g. a nbosomal protein promoter, provided such promoters are compatible with the host cell systems Preferably, however, a tissue- specific promoter is used. Tissue specific promoters include those specific for tissues of the immune system, including the CD2 promoter and the Lck promoter. Transcription of a DNA encodmgM2 may be increased by inserting an enhancer sequence into the vector Enhancers are relatively oπentation and position independent Many enhancer sequences are known from mammalian genes (e.g. elastase and globm) Enhancers for use with the invention are advantageously tissue-specific, and assist in endowing the M2 expression unit with tissue specificity The enhancer may be spliced into the vector at a position 5' or 3' to M2 DNA, but is preferably located at a site 5' from the promoter Advantageously, a eukaryotic expression vector encoding M2 may compπse a locus control region (LCR) LCRs are capable or directing high-level integration site independent expression of transgenes integrated into host cell chromatm, which is of importance especially where the M2 gene is to be expressed in the context of a permanently-transfected eukaryotic cell line m which chromosomal integration of the vector has occuπed, or in transgemc animals In the context of the present invention, the CD2 LCR is advantageously used, for example in combination with the CD2 promoter. Eukaryotic expression vectors will also contain sequences necessary for the termination of transcnption and for stabilising the mRNA. Such sequences are commonly available from the 5' and 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcπbed as polyadenylated fragments in the untranslated portion of the mRNA encoding M2. An expression vector includes any vector capable of expressing M2 nucleic acids that are operatively linked with regulatory sequences, such as promoter regions, that are capable of expression of such DNAs. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid. a phage, recombinant virus or other vector, that upon introduction into an appropπate host cell, results m expression of the cloned DNA. Appropπate expression vectors are well known to those with ordinary skill in the art and include those that are rephcable in eukaryotic and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome For example, DNAs encoding M2 may be inserted into a vector suitable for expression of cDNAs in mammalian cells, e.g a CMV enhancer-based vector such as pEVRF (Matthias, et al., (1989) NAR 17, 6418). Construction of vectors according to the invention employs conventional hgation techniques Isolated plasmids or DNA fragments are cleaved, tailored, and rehgated in the form desired to generate the plasmids required. If desired, analysis to confirm coπect sequences in the constructed plasmids is performed in a known fashion Suitable methods for constructing expression vectors, prepaπng in vitro transcπpts, introducing DNA into host cells, and performing analyses for assessing M2 expression and function are known to those skilled in the art Gene presence, amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcnption of mRNA, dot blotting (DNA or RNA analysis), or in situ hybπdisation, using an appropnately labelled probe which may be based on a sequence provided herein. Those skilled in the art will readily envisage how these methods may be modified, if desired. In a still further aspect, the invention relates to a method for arresting the growth of a cell compπsing inserting into the cell a transgene encoding an influenza virus M2 mutant according to the preceding aspects of the invention. Preferably, the method includes the steps of: (a) expressing in a cell a transgene encoding an influenza virus M2 mutant according to the invention under tissue-specific control; (b) cultuπng the cells in the presence an M2 blocking agent; and (c) cultuπng the cells in the absence of the blocking agent m order to induce growth aπest. The use of blocking agents, such as amantadme or πmantadine, permits the mutant according to the invention to function as a conditional lethal agent. Administration of a blocking agent to an animal, or a patient, whose cells express the mutant according to the invention, allows the regulation of the growth of the subject cells. Therefore, the growth of selected tissues may be regulated by administration of a small molecule drug such as amantadme or πmantadine or analogues thereof. In a further aspect of the present invention, it is a noted that πmantadine and analogues thereof are capable of crossing the blood brain barπer and the placenta. Hence, mutants according to the invention may be used to target neuronal function, by specifically ablating neural populations for the study of neurological phenomena or the treatment of neurological disorders The invention is descπbed below, for the purpose of illustration only, in the following examples Example 1 Preparation of M2 H37A mutant. General biochemical and molecular techniques used herein are descπbed in Sambrook et al., Molecular Cloning. A Laboratory Manual, (1989) Cold Spπng Harbor, USA. SEQ. LD. No. 1 shows the sequence of M2 protein from the Weybπdge isolate of influenza A virus. His 37 of this polypeptide is changed to Ala by mutating the codon encoding position 37 from GAC to GCC by PCR using the method of Kunkel et al., (1987) Enzymology 159:367. The mutated M2 gene is inserted in muπne MEL cells (Needham et al, (1992) NAR 20:997-1003, Deisseroth et al, (1975) PNAS (USA) 72.2682-2686). MEL cells are cultured in ccMEM medium containing 10% FCS and 200μg/ml geneticm at 37°C Mutant M2 protein is transiently expressed under control of the mouse β-globin promoter Since the promoter is leaky, M2 expression occurs even in the absence of induction Under these conditions, cells fail to grow, impeding the cloning of M2(H37A) mutants in the absence of Rimantadme In the presence of Rimantadme, however, the mutant can be cloned On addition of an inducing agent (DMSO) to cells transfected with the construct there is rapid growth arrest, but m the presence of Rimantadme this is preceded by two cell doublings before terminal differentiation and growth aπest The cell kinetics for cells expressing M2(H37A) in the presence of Rimantadme and DMSO are identical to those for cells expressing wild-type M2 in the presence of DMSO only Example 2 Construction of Lck/M2 H37A transgene A construct is made compπsing the M2 H37A sequence under the control of the tissue specific Lck promoter The Lck promoter is activated duπng T-lymphocyte differentiation from pluπpotent haematopoietic stem cells. Duπng early thymocyte development, at the transition between CD3 CD4 CD8 and CD3 " CD4 T CD8 , the Lck "proximal" promoter is switched on, and remains active until silenced at the single positive stage (CD4 + or CD8 + ), thereby providing a naπow window on T cell development. Previous attempts to use this promoter in conjunction with a Cre/lox gene ablation system have failed The Lck promoter is contained in the vector pl017, obtained from Chaffin et al, (1990) EMBO J. 9:3821-3829, which is constructed by inserting the 3.2kb muπne proximal lck promoter (Garvin et al, (1990) Int. Immunol 2.173-180) between the EcoRI and Smal sites of pUC19. It additionally contains a polylinker, introducing Spel, SacU, Sfil and Notl sequences. The sequence encoding mutant M2 polypeptide is inserted at the BamFR site ot pl017. The construct is subsequently micromjected into mouse eggs and transgemc mouse lines generated. Example 3 Transgenic mice expressing M2 H37A All founder animals are bred to produce transgenic lines. Some hemizygous founders are then examined. The animals examined either lack a thymus with only a thymic rudiment and a small number of immature peπpheral T cells, have severely reduced numbers of peπpheral T cells, or develop a thymoma Hemizygous transgenic animals are bred to produce homozygous transgenic lines. These animals have only very small thymic rudiments. Cells are removed from the lymphoid organs of homozygous or hemizygous transgenic animals, and control animals, and analysed by flow cytometry (FACS analysis) using anti- CD3, CD4 and CD8 antibodies stained with fluorescein isothiocyanate (FTTC) or phycoerythπn (PE). The results, for homozygous transgenic animals, are shown in Table 1. TABLE 1 Control Transgenic antibody Thymus Spleen Thymus Spleen CD4 " CD8 4 50 95 95 CD4 + CD8 + 74 - 1 1 CD4 + CD8 16 33 4 4 CD4 CD8 T 5 18 1 _ From the results presented m table 1, it can be seen that the cells deπved from the transgenic thymus are predominantly CD4 CD8 , suggesting an immature phenotype. whilst control animals are CD4 + CD8 ^ The CD4 CD8 cells seen in transgenic thymus tissue (95% v 4% in control tissue) represent the earliest thymic immigrants duπng development of the thymus It is believed that this is the result of the aπest of thymic tissue development at an early stage in development The CD4 CD8 cells seen in spleen are non-T cells and thus the percentage is not relevant to this analysis Example 4 Organ culture experiments The transgenic mice descnbed in example 3 have a substantially complete deletion of thymic tissue, resulting of activation of the M2 mutant under the control of the Lck promoter at an early stage in foetal development such that no early T-cells are formed and no feeders for T-cell development are present in the mouse. As a result, the lack of T- cells is not rescuable by the administration of πmantadine, since even on mactivation of the M2 mutant T-cell generation is not induced due to lack of suitable precursors In order to demonstrate rescue of T-cell development, organ cultures are established from 15 day old mouse embryos, substantially as follows descπbed by Jenkmson and Anderson, (1994) Curr. Opm. Immunol. 6:293-297. Embryo sacs are removed from 15-day pregnant mice and the embryos released by cutting the umbilical cord. The embryos are stored on ice; non-embryo tissue is discarded. Any abnormal embryos, or asynchronous embryos as judged by size, are also discarded at this stage Foetal thymic lobes are dissected from the embryo and cultured on Costar filters (Corning) on RPMI medium The filters are transfeπed to a new well of medium every day duπng the expeπment At between 7 and 10 days, the thymic lobes are harvested, transfeπed to an eppendorf tube containing 200 μl medium, and the cells separated by teasing out mechanically. The cells are then analysed by FACS as descπbed above In a second seπes of expenments. the thymic rudiments are cultured m the presence of nmantadine, and the cells analysed by FACS as descπbed above Culture m the presence of πmantadme is able to rescue T-cell production in the thymic rudiments. Use of an alternative promoter in the transgenic animals that would successfully aπest thymic development after the formation of early T-cells and T-cell feeders would thus result in the production of a rescuable phenotype

Claims: Claims. 1 A mutant of influenza virus M2 protein capable of aπesting the growth of a mammalian cell 2 A protein according to claim 1 which is deπved from the Weybπdge isolate of influenza A virus 3 A mutant according to claim 1 or claim 2, wherein the mutation is effected m a residue which is part of the transmembrane domain of influenza virus M2 5 A mutant according to claim 4 wherein the mutation is made at position 37 6 A mutant according to claim 5 wherein the mutation is at Hιs37, which is substituted with a residue selected from the group consiting of Ala, Gly, Ser, Arg and Glx 7 A transgenic non-human mammal encoding, within at least a subpopulation of the cells thereof, a transgene expressing an influenza virus M2 mutant according to any preceding claim 8 A transgenic animal according to claim 7 wherein the transgene is under tissue- specific control 9 A transgenic animal according to claim 8 wherein the transgene is under the control of one or more of a tissue-specific enhancer, a tissue-specific promoter and a tissue-specific LCR 10 A transgenic animal according to any one of claims 7 to 9 wherein the M2 transgene causes an arrest in the growth of cells 11 A transgenic animal according to claim 10. wherein the arrest is tissue-specific 12. A transgenic animal according to claim 10 or 11 wherein the aπest may be prevented by administration of an M2 blocking agent to the animal. 13. A method for arresting the growth of a cell compπsing inserting into the cell a transgene encoding an influenza virus M2 mutant according to any one of claims 1 to 6. 14. A method according to claim 13, compπsing the steps of: (a) expressing in a cell a transgene encoding an influenza virus M2 mutant according to any one of claims 1 to 6 under tissue-specific control, (b) cultuπng the cells in the presence an M2 blocking agent; and (c) cultuπng the cells m the absence of the blocking agent m order to induce growth aπest. 15. A genetic construct compπsmg a nucleic acid encoding an influenza M2 mutant according to any one of claims 1 to 6. 16 A genetic construct according to claim 15, wherein the nucleic acid encoding the influenza virus M2 protein is operatively linked to a tissue-specific control sequence.

Inventors: HAY ALAN JAMES, SKINNER ANITA, THOMAS DAVID BRIAN, HAY, ALAN, JAMES, SKINNER, ANITA, THOMAS, DAVID, BRIAN
Applicants: HAY ALAN JAMES, MEDICAL RES COUNCIL, SKINNER ANITA, THOMAS DAVID BRIAN, HAY, ALAN, JAMES, MEDICAL RESEARCH COUNCIL, SKINNER, ANITA, THOMAS, DAVID, BRIAN
Application year: 1999
Main classification: C12N15
IPC codes: A01K67, C07K14, C12N5, C12N15